Objective  To investigate the effect of dapagliflozin on blood pressure variability (BPV) and left ventricular mass index (LVMI) in patients with type 2 diabetes mellitus (T2DM) and hypertension.

Methods  Patients with T2DM complicated with hypertension admitted to Lishui Central Hospital from August 2021 to August 2022 were selected as the study subjects, and were treated with conventional treatment (control group) and dapagliflozin treatment (test group), respectively. The changes of BPV index, LVMI, blood glucose level and the incidence of adverse reactions were compared between the two groups.

Results  A total of 94 patients with T2DM and hypertension were included in the study, including 47 patients in the test group and 47 in the control group. The 24-hour diastolic blood pressure (DBP), 24-hour systolic blood pressure (SBP), 24-hour systolic standard deviation (SSD), 24-hour diastolic standard deviation (DSD), fasting blood glucose (FBG), 2-hour blood glucose (PG), glycated hemoglobin glycosylated hemoglobin (HbA1c), body mass index (BMI) and LVMI of the patients with T2DM and hypertension were significantly decreased in the two groups (P<0.05), and the 24-hour SBP, 24-hour DBP, 24-hour SSD, 24-hour DSD, FPG, 2-hour PG, HbA1c, BMI and LVMI in the test group were lower than those in the control group (P<0.05). The total incidence of adverse reactions between the test group and the control group was 10.64% and 4.26%, respectively, and the difference was not statistically significant (P>0.05).

Conclusion  Dapagliflozin can reduce LVMI and improve BPV and blood glucose levels in patients with T2DM and hypertension, and has a good safety profile.

1.林海玲, 阙万才. 某院2型糖尿病合并高血压老年患者的用药情况分析[J]. 海峡药学, 2020, 32(12): 168-171. [Lin HL, Que WC. Analysis of medication in elderly patients with type 2 diabetes and hypertension in a hospital[J]. Strait Pharmaceutical Journal, 2020, 32(12): 168-171.] DOI: 10.3969/j.issn.1006-3765.2020.12.067.

2.Wang Z, Zhu Y, Zhang Y, et al. Protective ffctsof AS-IV ondiabetic cardiomyopathy by improving myocardial lipid metabolism in rat models of T2DMP[J]. Biomed Pharmacother, 2020, 127: 110081. DO1: 10.1016/j.biopha. 2020.110081.

3.梁万添, 陈姣, 庞军刚, 等. 达格列净对糖尿病合并高血压患者左心室重构的影响分析[J]. 中华老年心脑血管病杂志, 2022, 24(6): 591-594. [Liang WT, Chen J, Pang JG, et al. Eeffect of dapagliflozin on left ventricular emodeling in DM patients with hypertension[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2022, 24(6): 591-594.] DOI: 10.3969/j.issn.1009-0126. 2022.06.009.

4.江洪, 农秋妮, 何玫, 等. 达格列净联合早期功能康复锻炼在布洛陀壮族糖尿病合并心衰患者中的应用及对心功能和血糖水平的影响研究[J]. 糖尿病新世界, 2021, 24(23): 10-13. [Jiang H, Nong QN, He M, et al. Application of dapagliflozin combined with early functional rehabilitation exercise in patients with diabetes complicated by heart failure in Buluotuo Zhuang nationality and its effect on heart function and blood glucose level[J]. Diabetes New World, 2021, 24(23): 10-13.] DOI: 10.16658/j.cnki.1672-4062.2021.23.010.

5.张楠, 阮丹杰, 刘新颖, 等. 达格列净对2型糖尿病合并高血压患者醛固酮/肾素浓度比值的影响[J]. 中华糖尿病杂志, 2022, 14(1): 63-67. [Zhang N, Ruan DJ, Liu XY, et al. Effect of dapagliflozin on aldosterone to renin ratio in patients with type 2 diabetes mellitus complicated with hypertension[J]. Chinese Journal of Diabetes Mellitus, 2022, 14(1): 63-67.] DOI: 10.3760/cma.j.cn115791-20210714-00381.

6.中华医学会糖尿病学分会. 中国2型糖尿病防治指南(2020年版)[J]. 国际内分泌代谢杂志, 2021, 41(5): 482-548. DOI: 10.3760/cma.j.cn115791-20210221-00095.

7.中国高血压防治指南修订委员会, 高血压联盟(中国), 中华医学会心血管病学分会, 等.中国高血压防治指南(2018年修订版)[J]. 中国心血管杂志, 2019, 24(1): 24-56. DOI: 10.3969/j.issn.1007-5410.2019.01.002.

8.贺连栋. 达格列净治疗高血压合并2型糖尿病患者临床效果分析[J]. 青海医药杂志, 2021, 51(2): 4-7. [He LD. Analysis of the clinical effect of daggligin on hypertension patients with type 2 diabetes[J]. Qinghai Medical Journal, 2021, 51(2): 4-7.] https://d.wanfangdata.com.cn/periodical/qhyyzz202102002.

9.Wish JB, Pergola P. Evolution of mineralocorticoid receptor antagonists in the treatment of chronic kidney disease associated with type 2 diabetes mellitus[J]. Mayo Clin Proc Innov Qual Outcomes, 2022, 6(6): 536-551. DOI: 10.1016/j.mayocpiqo.2022.09.002

10.蒋能美, 管鑫娟, 杨社珍. 生长停滞特异性蛋白6和C1q/肿瘤坏死因子相关蛋白4水平与2型糖尿病患者颈动脉粥样硬化的关联[J]. 实用临床医药杂志, 2023, 27(5): 123-127. [Jiang NM, Guan XJ, Yang SZ. Correlations of growth arrest specific 6 and C1q/TNF-related protein 4 with carotid atherosclerosis in patients with type 2 diabetes[J]. Journal of Clinical Medicine in Practice, 2023, 27(5): 123-127.] DOI: 10.7619/jcmp. 20223211.

11.Song ZM, Yang RT, Wang WX, et al. Association of healthy lifestyle including a healthy sleep pattern with incident type 2 diabetes mellitus among individuals with hypertension[J]. Cardiovasc Diabetol, 2021, 20(1): 239. DOI: 10.1186/s12933-021-01434-z.

12.刘姗姗, 罗力亚, 赵璨. 达格列净对老年2型糖尿病合并射血分数保留型心力衰竭患者的治疗效果及对心功能的影响[J]. 中国医药, 2022, 17(4): 539-543. [Liu SS, Luo LY, Zhao C. Curative effect of dapagliflozin on elderly patients with type 2 diabetes mellitus and heart failure with preserved ejection fraction and its impact on cardiac function[J]. China Medicine, 2022, 17(4): 539-543.] DOI: 10.3760/j.issn.1673-4777.2022.04.015.

13.郝雁红, 吴清, 李云, 等. 达格列净联合缬沙坦胶囊在2型糖尿病合并新发高血压患者中的应用效果[J]. 中国当代医药, 2021, 28(17): 67-70. [Hao YH, Wu Q, Li Y, et al. Application effect of Daglijing combined with Valsartan Capsules in pa-tients with type 2 diabetes mellitus complicated with newly developed hy-pertension[J]. China Modern Medcine, 2021, 28(17): 67-70.] DOI: 10.3969/j.issn.1674-4721.2021. 17.017.

14.胡小玲. 糖尿病肾病合并高血压使用达格列净联合沙库巴曲缬沙坦的效果[J]. 糖尿病新世界, 2021, 24(19): 96-98, 102. [Hu XL. Effect of dapagliflozin combined with sacubitril and valsartan in diabetic nephropathy with hypertension[J]. Diabetes New World, 2021, 24(19): 96-98, 102.] DOI: 10.16658/j.cnki.1672-4062.2021.19.096.

15.陈宇宁, 严萍, 刘如松. 达格列净治疗糖尿病合并高血压的临床效果[J]. 临床合理用药杂志, 2021, 14(31): 50-53. [Chen YN, Yan P, Liu RS. Clinical effect of daggligin on diabetes complicated with hypertension[J]. Chinese Journal of Clinical Rational Drug Use, 2021, 14(31): 50-53.] DOI: 10.15887/j.cnki.13-1389/r.2021. 31.016.

16.黄宝丰, 罗特丹, 姜昕. 老年高血压患者内在能力下降与血压变异性的相关性研究[J]. 中华老年心脑血管病杂志, 2022, 24(7): 709-712. [Huang BF, Luo TD, Jiang X. Correlation between decline in intrinsic capacity and blood pressure variability in elderly patients with hypertension[J]. Chinese Journal of Geriatric Heart Brain and Vessel Diseases, 2022, 24(7): 709-712.] DOI: 10.3969/j.issn.1009-0126.2022.07.010.

17.Eirini P, Marieta P, Charalampos L, et al. Dapagliflozin does not affect short-term blood pressure variability in patients with type 2 diabetes mellitus[J]. Am J Hypertens, 2021, 34(4): 404-413. DOI: 10.1093/ajh/hpaa207.

18.王会鑫, 杨再刚, 周正, 等. 达格列净片对老年2型DKD合并高血压患者尿蛋白的影响[J]. 西部医学, 2022, 34(2): 229-234. [Wang HX, Yang ZG, Zhou Z, et al. Effect of dapagliflozin tablet on urine protein in elderly patients with type 2 diabetic nephropathy complicated with hypertension[J]. Medical Journal of West China, 2022, 34(2): 229-234.] DOI: 10.3969/j.issn.1672-3511. 2022.02.015.

19.中华医学会糖尿病学分会. 中国2型糖尿病防治指南（2020年版）[J]. 中华糖尿病杂志, 2021, 13(4): 315-409. DOI: 10.3760/cma.j.cn115791-20210221-00095.

20.田艳娟, 李万森, 杨小东, 等. 达格列净在糖尿病肾病患者治疗中的应用及相关指标水平评估[J]. 现代医药卫生, 2021, 37(4): 651-653. [Tian YJ, Li WS, Yang XD, et al. Application of daggligin in the treatment of patients with diabetes nephropathy and evaluation of related indicators[J]. Journal of Modern Medicine & Health, 2021, 37(4): 651-653.] DOI: 10.3969/j.issn.1009-5519. 2021.04.033.

21.李凤莲. 硝苯地平联合替米沙坦治疗高血压合并2型糖尿病的疗效及对血脂、胰岛β细胞功能的影响 [J]. 黑龙江医学, 2023, 47(10): 1185-1187. [Li FL. The efficacy of nifedipine combined with telmisartan in the treatment of hypertension complicated with type 2 diabetes and its effects on blood lipids and islets of langerhans β The impact of cell function[J]. Heilongjiang Medical Journal, 2023, 47(10): 1185-1187.] DOI: 10.3969/j.issn. 1004-5775.2023.10.009.